Roche said it ended development of an obesity candidate after an interim analysis in a Phase 2 trial suggested the program had limited likelihood of meeting its endpoints. The company halted work on emugrobart (GYM329), which was being tested in combination with an anti-obesity injectable. Roche’s termination reflects the high attrition rate for obesity drug combinations where both efficacy durability and patient outcomes must justify continued development. The company’s decision narrows its obesity pipeline and returns resources to other programs as it assesses next steps.